New Power Morcellator Study Suggests Doctors’ Inability to Detect Uterine Sarcoma before Minimally-Invasive Surgery, Bernstein Liebhard LLP Reports

Share Article

The findings of research published in the American Journal of Obstetrics & Gynecology may affect the nationwide litigation involving power morcellator lawsuits.

Free Case Review
We continue to monitor medical studies relevant to power morcellation as we speak with women whose uterine cancer allegedly spread because of this procedure.

A new study lends evidence to the dangers of a surgical tool that has been tied to the spread of uterine cancer in a growing number of power morcellator lawsuits (, Bernstein Liebhard LLP reports.

According to research published online this month by the American Journal of Obstetrics & Gynecology, there may not be a way for doctors to detect uterine sarcoma before a woman undergoes a uterine morcellation procedure to remove fibroids. In turn, this may increase the risk for cancerous tissue to spread throughout her peritoneal cavity during surgery. Findings of this study were obtained by a team of researchers from Kaiser Permanente and released on December 11th, 2014.*

“We continue to monitor medical studies relevant to power morcellation as we speak with women whose uterine cancer allegedly spread because of this procedure,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices including power morcellators. The Firm is actively investigating claims on behalf of women who allegedly experienced the spread of undiagnosed uterine cancers due to uterine morcellation.

Power Morcellators and Cancer

Power morcellators are used in minimally-invasive hysterectomy and fibroid removal surgeries to cut up uterine tissue so that it can be more easily extracted via a small abdominal incision. The scrutiny surrounding the safety of these devices has grown steadily since April 2014, when the U.S. Food and Drug Administration (FDA) announced its investigation of their potential to disseminate undetected cancer cells into the peritoneal cavity. Doctors were discouraged at this time from using power morcellators until the federal agency could review its potential to diminish a woman’s chance for long-term survival, should the disease be upstaged to its most deadly stage, according to the alert.

The FDA followed up with its previous warning on November 24th, when they cautioned against using power morcellators in the majority of women who require fibroid removal surgeries and hysterectomies. The agency also announced its request that power morcellator manufacturers add the strongest possible warning—referred to as a black box warning—to their labeling.**

Women who were diagnosed with uterine cancer after undergoing a fibroid removal or hysterectomy procedure may be eligible to receive compensation for injury-related damages.Learn more about the risks of uterine morcellation by visiting Bernstein Liebhard LLP’s website. Obtain a free and confidential legal evaluation by calling 800-511-5092.

*, The American Journal of Obstetrics & Gynecology, December 11, 2014.
**, FDA, November 24, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website